FDA advisers vote to oppose Pfizer/BioNTech COVID-19 vaccine booster
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Pfizer's (PFE) and Astellas Pharma's Present Encouraging Data from Phase 3 ARCHES Study of XTANDI
September 20, 2021 5:46 AM EDTAstellas Pharma Inc and Pfizer Inc. (NYSE: PFE) announced today ahead of the European Society for Medical Oncology (ESMO) Congress 2021 that XTANDI® (enzalutamide) improved overall survival (OS) in the ARCHES study in men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer).... More
FDA Votes 18 Yes, 0 No for Pfizer (PFE) BioNTech SE (BNTX) Covid Vaccine Booster for 65+ and High Risk
September 17, 2021 4:23 PM EDTFDA Votes 18 Yes, 0 No for Pfizer (NYSE: PFE) BioNTech SE (NASDAQ: BNTX) Covid Vaccine Booster for 65+ and High Risk
Based on totality of scientific evidence available... do known and potential benefits outweigh known and potential... More
